Nasdaq:US$18.36 (+0.11) | HKEX:HK$29.30 (+0.95) | AIM:£2.96 (+0.06)
Search
Announcements
123
4
56789101112131415
found Documents: 748
Announcements & Press Releases, Oncology / Immunology | 4 Feb 2022

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China
Hong Kong, Shanghai & Florham Park, NJ — Friday, February 4, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel sele
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Jan 2022

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
Hong Kong, Shanghai & Florham Park, NJ –– Thursday, January 20, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, hi
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 19 Jan 2022

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, January 19, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 Jan 2022

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Jan 2022

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 12, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Admin
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Jan 2022

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China
— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 t
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Jan 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2021

Blocklisting Six Monthly Return
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2021

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Group | 20 Dec 2021

HUTCHMED Included in FTSE Russell Indexes
Hong Kong, Shanghai & Florham Park, NJ — Monday, December 20, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 15 Dec 2021

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, December 15, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on December 14, 2021, it granted share options under the Share Option Scheme adopted by HU
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 14 Dec 2021

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 14, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studies of HMPL-523 presented at the 63rd American Society for
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Dec 2021

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting
Hong Kong, Shanghai & Florham Park, NJ — Friday, December 10, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalima
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Dec 2021

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study[1], and to support global registrations —
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Dec 2021

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China
Hong Kong, Shanghai & Florham Park, NJ –– Friday, December 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021 negotiations with the China National Healthcare Security Adminis
Read More
HKEX - INSIDE INFORMATION (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Dec 2021

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Nov 2021

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, November 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at November 30, 2021, the issued share capital of HUTCHMED consisted
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 Nov 2021

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
— Follows important findings from the TATTON[1] study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 24, 2021: H
Read More
LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Nov 2021

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Monday, November 8, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be present
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Nov 2021

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Nov 2021

HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
— Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO — — In CALYPSO, savolitinib and IMFINZI® combination demonstrated a 57% confirmed response rate in PRCC patients with
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Oct 2021

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, October 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at October 29, 2021, the issued share capital of HUTCHMED consisted of
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 28 Oct 2021

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China
Hong Kong, Shanghai & Florham Park, NJ –– Thursday, October 28, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational s
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Oct 2021

Grant of Awards under Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, October 20, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on October 20, 2021, it granted conditional awards (“LTIP Awards”) under the Long Ter
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Oct 2021

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Sep 2021

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, September 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 30, 2021, the issued share capital of HUTCHMED consist
Read More
HKEX Overseas Regulatory Announcement (PDF)
2021, Announcements & Press Releases, Oncology / Immunology | 29 Sep 2021

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
2021, Announcements & Press Releases, Group | 29 Sep 2021

HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, September 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, further to its announcement in March 2021 and following receipt of regulatory
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Sep 2021

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 21, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Sep 2021

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
— Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for advanced neuroendocrine tumors —   Hong Kong, Shanghai & Florham Park,
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 Sep 2021

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma
Hong Kong, Shanghai & Florham Park, NJ — Monday, September 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Sep 2021

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET —   Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 8,
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 7 Sep 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 7, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3Kδ inhibitor HMP
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Group | 6 Sep 2021

HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
Hong Kong, Shanghai & Florham Park, NJ — Monday, September 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Company’s ordinary shares, which trade on The Stock Exchange of Hong Kong Limit
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Sep 2021

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 2, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on September 1, 2021, it granted share options under the Share Option Scheme adopted by HUT
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Sep 2021

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Aug 2021

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, August 31, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at August 31, 2021, the issued share capital of HUTCHMED consisted of 8
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 26 Aug 2021

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer
Hong Kong, Shanghai & Florham Park, NJ — Thursday, August 26, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Group | 23 Aug 2021

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 23, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been selected as a constituent stock of several indexes administered by Ha
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 Aug 2021

Electronic Communication of Corporate Information
Hong Kong, Shanghai & Florham Park, NJ — August 17, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that it has written to its shareholders regarding its intention to adopt electronic c
Read More
LSE RNS Announcement (PDF)Letter to UK shareholders (PDF)
Announcements & Press Releases, Regulatory Notice | 17 Aug 2021

Election of language and means of receipt of corporate communications
HKEX Announcement (PDF)Letter and reply form to new registered shareholders (PDF)Notification letter and request form to non-registered holders (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Aug 2021

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
- Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio - - Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milesto
Read More
LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Aug 2021

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jul 2021

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, July 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) hereby notifies the market that as at July 30, 2021, the issued share capital of HUTCHMED consisted of 864,11
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Jul 2021

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 28 Jul 2021

HUTCHMED Reports 2021 Interim Results and Provides Business Updates
ELUNATE® in-market sales1 rose 186%, reflecting impact of in-house sales force Received 1st approval in China for ORPATHYS® and 2nd approval in China for SULANDA® U.S. and E.U. applications for surufatinib both accepted Raised $615m2 gross pr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 28 Jul 2021

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbor MET amplification — Hong Kong, Shanghai & Florham Park, NJ —
Read More
LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Jul 2021

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering
Hong Kong, Shanghai & Florham Park, NJ — Friday, July 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that the stabilization period in connection with the Global Offering ended on J
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 16 Jul 2021

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 16 Jul 2021

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –   –  Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for
Read More
HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
123
4
56789101112131415